Yes, Restasis (cyclosporine 0.05%) can be used for sicca syndrome (dry eye disease), particularly for moderate dry eye with presumed inflammatory component.
Restasis is FDA-approved specifically to increase tear production in patients whose tear production is suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (dry eye/sicca syndrome) 1.
Treatment Algorithm for Sicca Syndrome
Mild Dry Eye
- Start with nonpreserved artificial tears (≥4 times daily)
- Address contributing factors (blepharitis, meibomitis, eyelid abnormalities)
- If inadequate response, escalate to moderate dry eye treatment 2
Moderate Dry Eye - When to Add Restasis
Add cyclosporine 0.05% (Restasis) when:
- Artificial tears alone are insufficient
- Tear production is presumed decreased due to ocular inflammation
- Patient has not undergone punctal occlusion or is not currently using topical anti-inflammatory drugs 1
Dosing: One drop twice daily, approximately 12 hours apart 1
Expected timeline:
- Some objective improvements (corneal staining) may appear by 6 months
- Success rates: 74% in mild, 72% in moderate, 67% in severe dry eye 2
- After 1 year of twice-daily therapy, some patients can reduce to once daily without losing benefit 2
Mechanism and Evidence
Cyclosporine works by:
- Inhibiting T-cell activation and inflammatory cytokine production
- Blocking mitochondrial apoptosis pathways
- Potentially increasing conjunctival goblet cell density 2
Key efficacy data:
- 10-mm increase in Schirmer test scores at 6 months (15% of treated vs 5% of vehicle patients) 2
- May function as a disease-modifying agent with prolonged improvement lasting median 20 months after stopping treatment 2
Important Caveats
Evidence limitations: A 2019 Cochrane review of 30 RCTs (4,009 participants) found inconsistent evidence regarding cyclosporine's effects on ocular discomfort and tear film parameters (fluorescein staining, Schirmer test, tear break-up time) 2. While it may increase goblet cells, evidence is lacking that this translates to improved mucus production 2.
Common adverse effects:
- Ocular burning (17% of patients) - typically mild to moderate 2
- Most common reason for discontinuation 2
Contraindications:
- Active ocular infections
- Contact lens wear during instillation (remove lenses, wait 15 minutes before reinsertion) 1
Alternative Considerations
If Restasis fails or is not tolerated:
- Lifitegrast 5% (FDA-approved 2016) - shows benefit in signs and symptoms over 3 months 2
- Short-term topical corticosteroids (loteprednol 0.25% for 2-4 weeks) to suppress acute inflammation 2
- Cyclosporine 0.09% (Cequa) - newer formulation with potentially better tolerability 3
Special Population: Sjögren's Syndrome
For sicca syndrome secondary to Sjögren's syndrome, the EULAR 2020 guidelines recommend cyclosporine A as Step 2 treatment for refractory/severe ocular dryness after artificial tears fail, before considering serum eye drops 4.
Bottom line: Restasis is appropriate for moderate-to-severe sicca syndrome when inflammation is suspected and artificial tears are inadequate, but set realistic expectations given mixed evidence on symptom improvement and prepare patients for potential burning sensation and delayed onset of benefit (months, not weeks).